ForteBio is now part of the Sartorius group. Click here for more

News

Apr 30, 2020 : Sartorius closes acquisition of selected assets of Danaher Life Sciences

Göttingen, April 30, 2020

Sartorius, a leading international partner of life science research and the biopharmaceutical industry, successfully closed the acquisition of selected life science businesses of Danaher Corporation. The transaction was completed on April 30, 2020, after receiving the required regulatory approvals.

“The acquisition of this portfolio is a further milestone for Sartorius. The assets we purchased are an excellent strategic and operational fit with both our divisions. We are very pleased to welcome approximately 300 new Sartorius employees and to combine our expertise to become even more relevant together for our biopharma and life science customers,” said Sartorius Executive Board Chairman and CEO Dr. Joachim Kreuzburg. Sartorius paid a purchase price of 825 million U.S. dollars for the acquisition and, upon execution of the purchase agreement on October 19, 2019, has been preparing for integration of the acquired businesses into the two divisions of the Sartorius Group. Despite the special conditions prevailing during the pandemic crisis, integration can therefore be initiated immediately following the closing.

The businesses acquired by Sartorius generated revenue of approximately 170 million U.S. dollars in 2019 and cover various laboratory and bioprocessing technologies, which are complementary to the portfolio lineups of both Sartorius divisions. The company’s broader offering as a result of the acquisition will support customers even more comprehensively in the development of biotech medicines and vaccines, as well as in the safe and efficient production of such pharmaceuticals. Sartorius is thus extending its market position in bioanalytics as well as in key areas of the manufacture of biotech medications.

The FortéBio business for label-free biomolecular characterization includes innovative protein analysis instruments, biosensors and reagents that are used in drug discovery and will be integrated into the Bioanalytics unit within the Sartorius Lab Products & Services Division. The products are based on patented biolayer interferometry technology and perform real-time analysis of various biomolecular interactions. FortéBio employs approximately 200 people worldwide, has production sites in Fremont, California, USA, and Shanghai, China, and accounts for close to half of the revenue generated by the acquired businesses.

With the chromatography systems and resins business also acquired, Sartorius is expanding the portfolio of its Bioprocess Solutions Division in the downstream processing area. This business addresses an essential step in the purification of biopharmaceuticals and encompasses both reusable and single-use equipment, columns and resins. Furthermore selected product groups in the areas of stainless steel hollow fiber and single-use technology tangential flow filtration systems and single-use flow kits will additionally strengthen the division’s portfolio lineup in downstream processing. A further asset to be allocated to the Bioprocess Solutions Division is the SoloHill business covering microcarrier technology and particle validation standards used in cell cultures and other bioprocesses. Together, these various business entities employ approximately 100 people at their sites in Portsmouth, U.K.; Cergy, France; Ann Arbor, Michigan, USA; and Hopkinton, Massachusetts, USA.

Sartorius already provided information on the impact of this transaction on its financial forecast for the current year in its first-quarter earnings release of April 21, 2020. You will find this publication here at https://www.sartorius.com/en/company/newsroom.

This press release contains forward-looking statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius assumes no liability for updating such statements in light of new information or future events. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version.

A profile of Sartorius

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2019, the company earned sales revenue of some 1.83 billion euros. At the end of 2019, more than 9,000 people were employed at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.

Contact Information:
Petra Kirchhoff
Head of Corporate Communications and Investor Relations
+49 (0)551.308.1686
petra.kirchhoff@sartorius.com
sartorius.com

Mar 11, 2020 : Vanderbilt Vaccine Center Acquires Octet HTX System to Speed Antibody Screening

SAN JOSE, Calif., March 11, 2020,/PRNewswire/ -- ForteBio, the Biologics Business Unit of Molecular Devices, today announced that to aid in the discovery of human therapeutic antibodies to viral infections like dengue fever and eastern equine encephalitis, the Vanderbilt Vaccine Center recently became one of the first academic institutes in North America to adopt ForteBio's Octet HTX system.  A centerpiece in the Biopharm industry, the Octet HTX system provides the capacity to screen large panels of antibodies in parallel, with an easy-to-use interface enabling from early career to advanced scientists in academia to quickly learn, develop assays for, and generate data.

When choosing lead candidates, the Vanderbilt Vaccine Center needs to make strategic decisions based on their characterization of many antibodies.  The speed and flexibility of the Octet HTX system allow them to collect more insight for more informed decision making.

"The time to generate data is extremely fast.  Within a week of being installed, the lab had already generated two large data sets," said Robert Carnahan, Ph.D., Associate Professor at Vanderbilt.

About Molecular Devices

Molecular Devices is one of the world's leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical, and biotherapeutic development. Included within a broad product portfolio are platforms for high throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe.

ForteBio is a business unit of Molecular Devices, offering products that span multiple technology vectors including analytical instrumentation and software, clone picking and imaging, and automation and customization of engineering solutions. Our customers perform crucial work in life sciences research across academic, government and industrial settings, including pharmaceutical research, development, and manufacturing.

Contact Information:
Craig Tin
Director, Regional Marketing
1 650 289 6862
Craig.Tin@moldev.com

Aug 12, 2019 : ForteBio introduces high precision Octet system biosensor for process development rigor

August 12, 2019 - ForteBio, the Biologics Business Unit of Molecular Devices, announced today at Bioprocessing Summit in Boston, the release of the new High Precision Streptavidin 2.0 (SAX2) biosensor for the Octet® platform. Focused on meeting customers’ needs to minimize variability from consumables, the SAX2 biosensors are controlled to meet the most stringent of assay precision requirements with <4% CV within lots and <20% between lots.

Streptavidin biosensors are used for quick and easy customization of biosensors to make quantitative and kinetic measurements with any biotin-tagged molecule. By applying a higher level of precision with SAX2, this flexible capture method can be more readily developed and qualified in downstream and regulated applications, such as product release testing, activity assays in manufacturing, and more.

“The SAX2 biosensor rounds out our product and service offerings to our GxP customers, giving them fast and reliable tools from qualifying instruments to validating methods and maintaining data integrity,” said Laurent Claisse, General Manager for ForteBio.

Visit https://www.fortebio.com/SAX2 to learn more.

About Molecular Devices

Molecular Devices is one of the world's leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe.

ForteBio is a business unit of Molecular Devices, offering products that span multiple technology vectors including analytical instrumentation and software, clone picking and imaging, and automation and customization of engineering solutions. Our customers perform crucial work in life sciences research across academic, government and industrial settings, including pharmaceutical research, development and manufacturing.

Contact Information:

Craig Tin
Director, Regional Marketing
1 650 289 6862
Craig.Tin@moldev.com

Jun 10, 2019 : Jubilant Biosys is first to add ForteBio's latest SPR System in India, for fragment screening and characterization of lead compounds

BENGALURU, KA, India and SAN JOSE, Calif., May 20, 2019 /PRNewswire/ -- Jubilant Biosys, a wholly owned subsidiary of Jubilant Life Sciences, announced today that it has recently added advanced Pioneer FE system to their platform of drug discovery solutions available to customers. The Pioneer FE system from ForteBio, the Biologics Business Unit of Molecular Devices, represents the next generation SPR instrumentation for label-free characterization of biomolecules. Sensitive enough to measure high affinity and covalent binding events, the Pioneer systems also uses a unique OneStep® gradient injection technology to facilitate fragment screening. Pioneer systems with OneStep technology can analyze up to 768 fragments in 24 hours, obtaining kinetics during the primary screen and eliminating the need for additional screens.

The Pioneer system is the first unit placed in India, and part of Jubilant's continuing investment in new technologies supporting their innovator customer needs. Said Marcel Velterop, President of Jubilant Biosys, "The addition of the Pioneer SPR system will significantly upgrade and speed up our small molecule hit-finding engine for novel target classes."

Greg Milosevich, President of Molecular Devices, commented, "We are pleased to have Jubilant adopt the Pioneer platform and look forward to supporting them and their customers' goals in fast-tracking small molecule drug discovery programs."

 

About Jubilant Biosys Limited

Jubilant Biosys, a subsidiary of Jubilant Life Sciences Ltd., an integrated global pharmaceutical and life sciences company, has presence in Bengaluru and Noida in India. Jubilant Biosys has demonstrated expertise across multiple therapeutic areas including but not limited to Oncology, Metabolic Disorders, Pain & Inflammation and CNS. Business models include both functional and integrated discovery services up to IND including GLP and GMP services, proprietary in-house innovation and strategic investments as the core components which are available for collaborative research, partnership and out licensing.

 

About Molecular Devices, LLC

Molecular Devices, one of the world's leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Within the broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and discovery of new therapeutics. Molecular Devices is committed to continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe.

 

Contact for Molecular Devices

Craig Tin Director, Regional Marketing 650-289-6862 Craig.Tin@moldev.com

 

Contact for Jubilant Biosys

Drishti Asthana Executive, Business Development Jubilant Chemsys Limited +919899033635 Drishti.Asthana@jchemsys.com

Mar 12, 2019 : ForteBio Introduces New Product for High throughput Glycan Screening

March 12, 2019 - ForteBio, the Biologics Business Unit of Molecular Devices, announced today the availability of a new assay kit for high throughput glycan screening at the BioProcess International (BPI) West 2019 conference. The Sialic Acid (GlyS) kit, which is designed for use on the industry leading Octet® instruments, presents a revolutionary opportunity to screen for optimal sialylation faster, earlier in development, and with more samples than allowed by conventional techniques.

Said Greg Milosevich, President of Molecular Devices, "The GlyS kit is part of the ForteBio promise for workflow and product innovations that help our customers make better informed decisions sooner, to reduce risk and time in development." The GlyS kit, available for use on all Octet systems is compatible with crude samples — no purification or digestion steps required. Relative sialylation results can then be combined in the software with titer data obtained on the Octet system to select clones that have high protein expression as well as optimal sialic acid content during early screening in cell line development.

Visit GlyS kit to learn more.

About Molecular Devices
Molecular Devices is one of the world's leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe.

ForteBio is a business unit of Molecular Devices, offering products that span multiple technology vectors including analytical instrumentation and software, clone picking and imaging, and automation and customization of engineering solutions. Our customers perform crucial work in life sciences research across academic, government and industrial settings, including pharmaceutical research, development and manufacturing.

Contact Information:
Craig Tin
Director, Regional Marketing
1 650 289 6862
Craig.Tin@moldev.com

Apr 26, 2018 : Molecular Devices and ForteBio combine to create new Biologics Solutions business unit to drive integrated workflow offerings for drug discovery and development

San Jose, CA, April 26, 2018 — Molecular Devices, LLC, a leader in protein and cell biology technologies, today announced the combination of its Biologics BioTherapeutics division with Pall Corporation’s ForteBio division—a world leader in label-free analysis for biomolecular detection and characterization that accelerates drug discovery and development.

The combined entity, called Biologics Solutions, will operate as a business unit within Molecular Devices and will involve the transition of all personnel and technology from Pall ForteBio to Molecular Devices, both operating companies of Danaher, a global science and technology innovator.

“We are bringing together the best in protein analysis and characterization, and the best in clone selection as a unified team to provide integrated workflow solutions for cell line development in biologics process development,” said Greg Milosevich, President of Molecular Devices. “By combining Pall’s ForteBio business with Molecular Devices Biologics BioTherapeutics division, we will offer streamlined and responsive support for improved customer confidence and save precious time in customer research, discovery, and drug development.”

The increasing number of approved biologics and biosimilars in recent years has fueled the demand for technologies that enhance productivity in drug discovery and development. Currently, large numbers of hybridoma and cell clones have to be screened in early development stages for a number of product characteristics to select lead molecules and identify rare stable high producer clones. By integrating the teams that offer protein analysis technologies at ForteBio and clone picking technologies at Molecular Devices, the Biologics Solutions unit will improve the speed and efficiency in selecting lead molecules, generating highly productive cell lines and developing processes for manufacturing. The business unit will launch a newly combined ‘go-to-market’ team to expand its reach and service to its customers, improve customer intimacy, and offer truly integrated workflow solutions for therapeutic drug discovery and development.

Beginning in July 2018, the Biologics Solutions business unit will manage both the ForteBio and Biologics BioTherapeutics product portfolios under the newly created biologics brand within Molecular Devices.

About Molecular Devices
Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe.

For more information, please visit www.moleculardevices.com

Contact Information:
Craig Tin
Director of Marketing
1 650 289 6862
craig.tin@pall.com

Jan 03, 2018 : Obsolescence Notification for OCTET QK384 System

Pall ForteBio is announcing the end of the sale of new and refurbished Octet QK384 systems worldwide on January 3, 2018. The Octet QK384 systems will reach their end of guaranteed support (EGS) on December 31, 2022. As you approach the end of the guaranteed support period, you have the choice of upgrading your system or continuing support on your Octet QK384 system.

Pall ForteBio is committed to providing the highest level of customer care for all our products. Please see below for key timelines and support options that are now available for the Octet QK384 systems.

  • January 3, 2018: End of sale of new and refurbished Octet QK384 systems
  • December 31, 2021: Last day to purchase annual Service Contracts for Octet QK384 systems*
  • December 31, 2022: End of guaranteed support for Octet QK384 systems

*Last day to purchase annual Service Contracts for the specified system, covering up to the EGS date. After the EGS date, Pall ForteBio will continue to offer time and materials support on a best-effort basis.

Replace Your Instrument
Our Octet systems have evolved significantly in recent years and this presents an opportunity to step into a new dimension of performance. We have attractive trade-in offers in place to facilitate a smooth transition from the Octet QK384 system to an Octet RED384, HTX system, or the newly launched Octet RED96e systems.

Keep Your Instrument
You can continue to purchase comprehensive and basic service contracts, performance maintenance, and certification offerings for the Octet QK384 system that is valid up until the EGS date. After that date, on-demand services can be purchased on a time-and-materials basis but parts availability is not guaranteed.

We’re Here to Help
For more information, please contact your local sales or service representatives or fill out our technical support form.

We use cookies to personalize content and improve your browsing experience.

We also use analytics & advertising services. To opt-out click for more information.